Skip to main content
. Author manuscript; available in PMC: 2014 Aug 18.
Published in final edited form as: Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504

Fig. 4. CD8+ T cells contribute to Treg proliferation in the tumor site in vivo.

Fig. 4

B16 cells were injected subcutaneously in WT mice treated with CD8-depleting antibody or isotype control. Twenty-four hours after BrdU pulse, given on day 7 after tumor inoculation, tumor and tumor-draining lymph node were analyzed for the amount of proliferated CD4+FoxP3+ Tregs. (A) PercentageofFoxP3+ cells detected within the CD4+ T cell fraction either BrdU− (black) or BrdU+ (gray) (n = 6 out of two independent experiments; shown as mean ± SEM). (B) Fraction of proliferated (BrdU+) cells detected within the total Treg fraction (CD3+CD4+FoxP3+) in tumor (left) and tumor-draining lymph node (right). Using a two-sided Mann-Whitney U test to compare the two proliferated fractions, we confirmed a significantly reduced proliferation rate within the tumor-infiltrating Tregs under CD8-depleting conditions. *P =0.002; **P = 0.0094.